

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Böss, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/008880

Title: Selective Phosphodiesterase 9A Inhibitors as Medicaments for Improving Cognitive Processes

**MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,


Susan M. Pellegrino

Reg. No.: 48,972
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Facsimile: (203) 812-6459

INFORMATION DISCLOSURE CITATION

Applicant(s)

1. $\text{Applicand}(S)$

Böss, et al.

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

/PEZ/	R1	Database Medline, US National Library of Medicine (NLM), Bethesda, MD, US, 1997. Schousboe, et al., "Role of Ca+2 and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neurodegeneration: Clinical Perspectives." Database Accession No. NLM9186041. Zusammenfassung & Clinical Neuroscience, New York, NY, 1997.
/PEZ/	R2	Fischer, et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-Specific Phosphodiesterase," <i>J. of Biological Chemistry</i> , <u>273</u> (25): 15559-15564 (1998).

EXAMINER

/Paul Zarek/

DATE CONSIDERED

08/22/2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.